X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with THOMAS COOK INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs THOMAS COOK INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

THOMAS COOK INDIA 
   Change

Thomas Cook India (TCIL) offers a broad spectrum of leisure travel related services such as package tours, currency exchange and travel insurance as well as hotel and flight reservations. TCIL has been present in India for 128 years. In 2006, the com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES THOMAS COOK INDIA INDOCO REMEDIES/
THOMAS COOK INDIA
 
P/E (TTM) x 37.4 33.5 111.5% View Chart
P/BV x 2.9 6.0 48.8% View Chart
Dividend Yield % 0.8 0.2 501.5%  

Financials

 INDOCO REMEDIES   THOMAS COOK INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
THOMAS COOK INDIA
Mar-17
INDOCO REMEDIES/
THOMAS COOK INDIA
5-Yr Chart
Click to enlarge
High Rs360238 151.3%   
Low Rs249166 150.4%   
Sales per share (Unadj.) Rs119.0234.2 50.8%  
Earnings per share (Unadj.) Rs8.42.1 394.9%  
Cash flow per share (Unadj.) Rs15.24.4 344.2%  
Dividends per share (Unadj.) Rs1.600.38 421.1%  
Dividend yield (eoy) %0.50.2 279.0%  
Book value per share (Unadj.) Rs70.741.5 170.5%  
Shares outstanding (eoy) m92.15366.76 25.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.9 297.0%   
Avg P/E ratio x36.495.3 38.2%  
P/CF ratio (eoy) x20.045.6 43.9%  
Price / Book Value ratio x4.34.9 88.5%  
Dividend payout %19.117.9 106.6%   
Avg Mkt Cap Rs m28,08374,049 37.9%   
No. of employees `0006.02.3 264.2%   
Total wages/salary Rs m2,16740,539 5.3%   
Avg. sales/employee Rs Th1,817.037,584.2 4.8%   
Avg. wages/employee Rs Th359.017,741.3 2.0%   
Avg. net profit/employee Rs Th127.7339.9 37.6%   
INCOME DATA
Net Sales Rs m10,96885,880 12.8%  
Other income Rs m40750 5.3%   
Total revenues Rs m11,00786,630 12.7%   
Gross profit Rs m1,5653,319 47.1%  
Depreciation Rs m633846 74.8%   
Interest Rs m621,309 4.7%   
Profit before tax Rs m9091,914 47.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1391,138 12.2%   
Profit after tax Rs m771777 99.2%  
Gross profit margin %14.33.9 369.2%  
Effective tax rate %15.359.5 25.6%   
Net profit margin %7.00.9 777.0%  
BALANCE SHEET DATA
Current assets Rs m5,72534,451 16.6%   
Current liabilities Rs m5,45432,401 16.8%   
Net working cap to sales %2.52.4 103.4%  
Current ratio x1.01.1 98.7%  
Inventory Days Days620 19,440.5%  
Debtors Days Days7240 179.9%  
Net fixed assets Rs m5,30722,384 23.7%   
Share capital Rs m184367 50.2%   
"Free" reserves Rs m6,33114,840 42.7%   
Net worth Rs m6,51615,206 42.8%   
Long term debt Rs m1,3237,376 17.9%   
Total assets Rs m11,97064,131 18.7%  
Interest coverage x15.62.5 635.4%   
Debt to equity ratio x0.20.5 41.9%  
Sales to assets ratio x0.91.3 68.4%   
Return on assets %7.03.3 213.9%  
Return on equity %11.85.1 231.6%  
Return on capital %12.414.3 86.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,507333 1,352.6%   
Fx outflow Rs m1,141125 910.2%   
Net fx Rs m3,366208 1,619.6%   
CASH FLOW
From Operations Rs m8862,855 31.0%  
From Investments Rs m-1,706-2,665 64.0%  
From Financial Activity Rs m1,3161,551 84.8%  
Net Cashflow Rs m4971,779 27.9%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 0.2 6,250.0%  
FIIs % 6.0 12.4 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 12.4 180.6%  
Shareholders   12,805 34,019 37.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TIL LTD  ADANI PORTS & SEZ  COX & KINGS  TVS SRICHAKRA  EDELWEISS FINANCIAL  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

THOMAS COOK INDIA Announces Quarterly Results (1QFY19); Net Profit Down 4.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, THOMAS COOK INDIA has posted a net profit of Rs 648 m (down 4.3% YoY). Sales on the other hand came in at Rs 21 bn (down 24.5% YoY). Read on for a complete analysis of THOMAS COOK INDIA's quarterly results.

THOMAS COOK INDIA Announces Quarterly Results (4QFY18); Net Profit Down 99259.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, THOMAS COOK INDIA has posted a net profit of Rs 59 bn (down 99259.2% YoY). Sales on the other hand came in at Rs 26 bn (up 24.9% YoY). Read on for a complete analysis of THOMAS COOK INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS